 What we're announcing is a co-development agreement, one of our technologies from the Institute, that looks at delivering a new drug candidate to treat parainfluenza virus, a viral infection that has no cure and no preventative at this point in time. It causes croupin kids, causes bronchiolitis as well as pneumonia and bronchitis, both in children as well as in the elderly, typically with immunocompromised people and cancer patients. There's a greater than 50% mortality rate as a consequence of this virus when they get infected. Normally we would be investing in relatively mature, lay-stage development projects, but this one is of paramount importance to the general health care of a large population and we believe that this is the right place and the right people that we're working with to make this work. There are basically no competitive technologies in the development pathway that are small molecules and therefore we're very confident that we'll actually be able to take this drug candidate right the way through to market with China Grand Pharma as a partner. We know that China Grand Pharma have fantastic manufacturer expertise, they have fantastic global distribution expertise and using that expertise, once we've gone through the clinical work, we can actually get this drug out to the market and to the people, the patients where it's needed most. Using that structure-informed drug discovery process, this project is so much more advanced. We see now the end in sight to deliver a new drug candidate that can be ready for human phase one clinical trials in short time.